BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 18, 2025
See today's BioWorld
Home
» Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III
To read the full story,
subscribe
or
sign in
.
Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III
March 31, 2011
By
Catherine Shaffer
No Comments
Amgen Inc. and Takeda Pharmaceutical Co. Ltd. shared their disappointment today regarding top-line results of a Phase III trial of their VEGF inhibitor, motesanib, for nonsquamous non-small-cell lung cancer (NSCLC).
BioWorld
